Transforming Patients' Lives
OX1406 (anti beta2-GPI) is a modified antibody which binds to beta 2 glycoprotein I.
This product was specifically designed to target the main pathogenetic mechanism of the antiphosholipid syndrome (Hughes syndrome, or APS), a rare disease characterized by multiple and recurrent thromboses.
OX1406 prevent thromboses in APS by competing with antiphospholipid antibodies for the binding to beta2-GPI.
OX1406 is outlicensed to Aura Biopharm
For more information, please see the following references or contact us:
OncoNOx ApS - Ole Maaløes Vej 3 - 2200 Copenhagen - Denmark